These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 11045166

  • 1. [Micronized fenofibrate and LDL-cholesterol subfractions].
    Soska V.
    Vnitr Lek; 1999 Jul; 45(7):441-3. PubMed ID: 11045166
    [Abstract] [Full Text] [Related]

  • 2. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.
    Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
    [Abstract] [Full Text] [Related]

  • 3. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C, Lilli S, Gentile A, Patti L, Di Marino L, Cipriano P, Riccardi G, Rivellese AA.
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [Abstract] [Full Text] [Related]

  • 4. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K.
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [Abstract] [Full Text] [Related]

  • 5. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
    Zhu J, Ye P.
    Chin Med J (Engl); 2003 Jun; 116(6):840-3. PubMed ID: 12877791
    [Abstract] [Full Text] [Related]

  • 6. [Effect of fibrates on VLDL and LDL lipoprotein composition and parameters of their oxidation in hypertriglyceridemia].
    Zeman M, Zák A, Tvrzická E, Konárková M, Stípek S.
    Cas Lek Cesk; 2002 Apr 12; 141(7):211-6. PubMed ID: 12053756
    [Abstract] [Full Text] [Related]

  • 7. [Dyslipidemia in diabetes mellitus].
    Niemeijer-Kanters SD, Banga JD, Erkelens DW.
    Ned Tijdschr Geneeskd; 2001 Apr 21; 145(16):769-74. PubMed ID: 11346913
    [Abstract] [Full Text] [Related]

  • 8. [Effect of micronized fenofibrate (lipantyl-200M) on synthesis of cholesterol in peripheral blood lymphocytes of patients with ischemic heart disease and hyperlipidemia].
    Ivanova TN, Poliakova ED, Olfer'ev AM, Perova NV.
    Biull Eksp Biol Med; 1998 May 21; 125(5):569-73. PubMed ID: 9644562
    [No Abstract] [Full Text] [Related]

  • 9. [Present status of fibrates in the treatment of hyperlipoproteinemias].
    Soska V.
    Vnitr Lek; 1999 Jul 21; 45(7):438-40. PubMed ID: 11045165
    [Abstract] [Full Text] [Related]

  • 10. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH.
    Am J Cardiol; 2008 Dec 22; 102(12A):41L-47L. PubMed ID: 19084089
    [Abstract] [Full Text] [Related]

  • 11. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov 22; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

  • 12. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A.
    Diabetes Metab Res Rev; 2008 Nov 22; 24(4):286-93. PubMed ID: 18273835
    [Abstract] [Full Text] [Related]

  • 13. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
    Wu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC.
    Ann Clin Lab Sci; 2007 Nov 22; 37(2):158-66. PubMed ID: 17522372
    [Abstract] [Full Text] [Related]

  • 14. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun 22; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 15. FIELDS of dreams, fields of tears: a perspective on the fibrate trials.
    Wierzbicki AS.
    Int J Clin Pract; 2006 Apr 22; 60(4):442-9. PubMed ID: 16620358
    [Abstract] [Full Text] [Related]

  • 16. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 22; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 17. [Favorable effects of decreasing lipids in patients with diabetes mellitus].
    Gouni-Berthold I, Krone W.
    Dtsch Med Wochenschr; 2006 Dec 22; 131 Suppl 8():S252-4. PubMed ID: 17139581
    [Abstract] [Full Text] [Related]

  • 18. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G.
    Am J Cardiol; 2008 Dec 22; 102(12A):28L-33L. PubMed ID: 19084087
    [Abstract] [Full Text] [Related]

  • 19. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May 22; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 20. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
    Dierkes J, Westphal S, Luley C.
    Expert Opin Drug Saf; 2004 Mar 22; 3(2):101-11. PubMed ID: 15006716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.